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Liver cirrhosis is associated with higher morbidity and reduced survival with appearance of portal hypertension and resultant
decompensation. Portal decompression plays a key role in improving survival in these patients. Transjugular intrahepatic
portosystemic shunts are known to be eﬃcacious in reducing portal venous pressure and control of complications such as
variceal bleeding and ascites. However, they have been associated with signiﬁcant problems such as poor shunt durability,
increased encephalopathy, and unchanged survival when compared with conservative treatment options. The last decade has seen
a signiﬁcant improvement in these complications, with introduction of covered stents, better selection of patients, and clearer
understanding of procedural end-points. Use of TIPS early in the period of decompensation also appears promising in further
improvement of survival of cirrhotic patients.
1.Introduction
Portal hypertension is a universal consequence of cirrhosis,
responsible for many important complications such as
variceal bleeding, ascites, hepatic encephalopathy, hepato-
renal syndrome, and hepatic insuﬃciency. The onset of
these complications marks the transition of liver disease
from a compensated to a decompensated stage. Each year,
approximately 5 to 7% of cirrhotic patients advance to
decompensation, and this is associated with a reduction
in survival from a median of 12 years to just 2 years
[1]. Liver transplantation is the only therapy that improves
survival and quality of life of such patients. Unfortunately
the shortage of donors has limited its role in most parts of
the world. Hence, other therapeutic measures are required to
manage complications of cirrhosis and prolong survival of
patients with decompensated cirrhosis.
Pharmacological and endoscopic therapies are simple
and eﬀective in control of PHT in majority of patients.
Meta-analysis of many studies have clearly demonstrated
that nonselective beta blockers and endoscopic band ligation
are useful in primary and secondary prophylaxis of variceal
bleeding, and that such interventions signiﬁcantly improve
survival in patients with cirrhosis [2]. Despite these good
results of endoscopy and pharmacotherapy, 10–15% of
patients have refractory or recurrent bleeding [3]. Pharma-
cotherapy has hardly any eﬀects on other complications of
cirrhosis, like ascites and hepatorenal syndrome. Endoscopic
therapyalsodoesnotreduceportalpressureandsoobviously
has no eﬀect on complications like ascites and hepatorenal
syndrome.
For many years, surgical shunts were used in patients
that did not respond to medical therapy. However, surgery
is associated with signiﬁcant morbidity and mortality in
patients with decompensated liver disease [4]. Transjugular
intrahepatic portosystemic shunts (TIPS) were introduced
as an alternative to surgery in the 1990s and have since
gained acceptance worldwide to replace surgical shunts in
most centres where TIPS are available.
2. Effects of TransjugularIntrahepatic
Portosystemic Shunts
TIPS is a portosystemic shunt created within the liver
parenchyma with the help of a stent placed between the2 International Journal of Hepatology
hepatic vein and portal vein. It behaves like a side-to-
side portocaval shunt, causing a direct reduction of portal
venous pressure, to achieve an ideal portosystemic gradient
of less than 12mm of Hg required for adequate portal
decompression and prevention of variceal bleeding [5]. The
reductioninportalvenouspressurealsoreducestheﬁltration
into the peritoneal space, allowing lymphatic absorption of
ascitic ﬂuid and thereby control of ascites and hydrothorax
[6]. Additionally, TIPS increases glomerular ﬁltration and
urine output, promotes natriuresis, and reduces the plasma
rennin activity, aldosterone levels, and noradrenaline levels.
All these help in improving the renal function that is
altered from advanced cirrhosis [7, 8]. TIPS also improves
protein metabolism and nutrition, alongwith an overall
improvement in quality of life [9, 10].
TIPS has been well studied in various randomized con-
trolled trials and nonrandomized studies, based on which,
it has been recommended for various indications (Table 1)
[11].
3. Strategiesto ImproveSurvivalof Patients
Undergoing TIPS
Initial studies showed TIPS to be highly eﬀective in control-
ling variceal bleeding and ascites compared to conventional
methods like endoscopic therapy, pharmacotherapy, and
large-volumeparacentesis[12–29].Despitesuchhighsuccess
r a t e ,t h e r ew a sn os u r v i v a la d v a n t a g ed u et oT I P S .I n
addition, morbidity due to hepatic encephalopathy and
deterioration of liver function made the procedure less
attractive. The last decade, however, witnessed a resurgent
interest in the procedure, largely due to better outcome
of TIPS from improvement in the TIPS device and better
selection of patients.
3.1. Use of Stent-Graft Device for TIPS. Restenosis of TIPS
has been the bug-bear of TIPS for many years, occurring
in 18% to 78% of all TIPS [11]. When it occurs, it almost
invariably results in reappearance of symptoms of portal
hypertension and would require a secondary procedure such
as balloon angioplasty and/or insertion of another stent to
improve its patency. Stenosis usually occurs within the stent
or along the outﬂow hepatic vein. Permeation of bile and/or
mucin has been implicated by some investigators to be the
cause of this stenosis [30]. In an attempt to improve its
patency, covered stents or stent-grafts were introduced, with
the concept that a PTFE covering would prevent bile/mucin
permeation and tissue proliferating into the TIPS [31].
Initial recommendation was to use these covered stents for
revision of dysfunctional bare-stent TIPS, but as conﬁdence
grew, de novo use was strongly encouraged, and it is now
the recommended device for almost all TIPS. The covered
stent has been used over a decade now, and the results in
large cohort and comparative studies clearly demonstrate its
superiority over bare stents [32–36]. The patency of covered
stentsisapproximately>85%patencyrateat1year,amarked
improvement from the 40–60% patency noted with bare
stents at that period. The patency is enhanced further if the
TIPS device is positioned appropriately, that is, extending all
the way to the IVC [32]. The improved patency has resulted
in a clear reduction in recurrence of portal hypertension
and also the number of reinterventions needed to improve
TIPS patency. Additionally, covered stents oﬀer a signiﬁcant
survival beneﬁt. In a large, retrospective study by Angermayr
et al., the 3-month, 1-year, and 2-year survival rates were
93%, 88%, and 76% for covered stent TIPS and 83%, 73%,
and 62% for bare stent TIPS [37]. Similar outcomes have
been described in many other studies too [27, 38, 39].
Yang et al. recently reported a meta-analysis on patency
and clinical outcomes of TIPS comparing ePTFE-covered
stents and bare stents, based on 1 randomized trial and 5
retrospective studies, involving more than 1200 patients. The
ﬁndings are of improved shunt patency of covered stents
without increasing the incidence of hepatic encephalopathy,
and there was a trend towards improved survival at the
end of one year [40]. A similar meta-analysis based on 8
studies (1 randomized controlled trial and 7 retrospective
studies) and 479 patients was presented as an abstract at
the Digestive Diseases Week meeting last year. The authors
likewise concluded that covered stents much better overall
survivalthanbarestents,withpooledoddsofoverallsurvival
at 1 year being 2.37 times more in the PTFE group as
compared to bare TIPS group [41].
3.2. Identiﬁcation of High-Risk Patients and Appropriate
Patient Selection. When TIPS were performed in the early
years,theywereoﬀeredtoavarietyofpatientswithproblem-
aticvaricealbleedingorascites,oftenregardlessoftheunder-
lying clinical status. Hence the initial years saw TIPS-related
liver failure and mortality reaching up to 44%, making it at
times a worse option than conservative therapy. Subsequent
eﬀorts were made towards identifying the high-risk patients
that were likely to decompensate following TIPS. Clinical
and biochemical factors identiﬁed include advanced age,
pre-existing encephalopathy, presence of ascites, increased
prothrombin time, elevated bilirubin level, low sodium and
albumin levels, and emergent indication for TIPS [42–45].
Various clinical-biochemical scoring systems (Child-Pugh
score,MELDscore,Emoryscore,andAPACHEIIscore)were
also described to help prognosticate and counsel patients
beingconsideredforTIPS[46–50].Ingeneral,pooroutcome
is expected in patients undergoing TIPS with a Child-Pugh
score >12, MELD score >18, Emory score >3, or an APACHE
II score >18. While all these scoring systems are reasonably
accurate, the MELD score is considered superior—most in
predicting long-term survival following TIPS [50]. Judicious
selection of patients using these indices could potentially
prevent mortality from a TIPS procedure.
3.3. Prevention and Control of Post-TIPS Hepatic Encephalo-
pathy (HE). Perhaps the most unresolved problem of TIPS
has been encephalopathy. 30–35% of patients have HE
following TIPS which largely related to diversion of toxins
and portal hypoperfusion [51, 52]. It is mild, transient,
and episodic on most occasions and can be easily managed
conservatively. Also, the frequency and intensity of HE tendsInternational Journal of Hepatology 3
Table 1: Indications for TIPS.
(1) Acute variceal bleeding unresponsive to medical and endo-
scopic therapy
(2) Recurrent variceal bleeding unresponsive to medical and
endoscopic therapy
(3) Ectopic variceal bleeding (e.g., bleeding from duodenal
varices, rectal varices, stomal varices, caput medusae, etc.)
(4) Nonvariceal bleeding secondary to hypertensive gastropathy/
enteropathy
(5) Ascites resistant or intolerant to optimal medical therapy
(6)Hepatichydrothoraxresistantorintoleranttooptimalmedical
therapy
(7) Budd-Chiari syndrome
(8) Hepatorenal syndrome
(9) Hepatopulmonary syndrome
(10) Veno-occlusive disease
to diminish with time, probably from cerebral adaptation to
gut-derived neurotoxins [53]. However, about 3–7% of the
TIPS tend to have recurrent or refractory encephalopathy,
necessitating shunt occlusion or reduction.
Post-TIPS encephalopathy is anticipated to be higher
with a wider shunt lumen. Thus, its frequency and severity
would expectantly be higher with covered stents, as its
diameter remains unchanged over a long period of time,
unlike bare-stents, which show progressive reduction of the
shunt diameter from intimal hyperplasia. Interestingly, not
only has the incidence of HE been found to be similar with
either device, but also some studies have in fact showed a
lower frequency of HE with covered stents [54].
Prevention of HE is diﬃcult, predicted vaguely by
presence of pre-TIPS encephalopathy, renal impairment,
advanced age, female sex, nonalcoholic etiology of liver
disease, severity of liver disease, hypoalbuminemia, and
higher degree of portal decompression [9, 12, 51, 52, 55–
58]. While there is a general consensus that too much
decompression is detrimental, it is diﬃcult to estimate how
much would be ideal. Most interventionists would prefer to
reduce the portosystemic gradient to not more than half the
pre-TIPS level, and certainly not below 5mmHg [59]. This
can be achieved by under-dilating the TIPS device at time of
insertion and then expanding it further to attain the desired
portosystemic gradient or clinical outcome. Additional
embolisation of competing portosystemic shunts would help
reduce further diversion and potentially increase hepatic
portal inﬂow. Use of smaller diameter shunts, especially in
higher risk patients, has also been considered to reduce the
risk of encephalopathy. However, a recent randomized trial
by Riggio et al. comparing 8mm and 10mm shunts clearly
showed no diﬀerence in encephalopathy rates. The authors
additionally showed the 8mm shunts to be ineﬀective in
portal decompression and hence do not recommend their
use over the 10mm shunts, even in high-risk cases [60].
3.4. Use of TIPS in Early Decompensation of Cirrhosis. The
next game-changer, arguably, involves the use of TIPS at a
much earlier stage of decompensation. For many years, TIPS
has been used to treat complications of portal hypertension
after conventional medical therapy has been exhausted. In
a recent landmark publication by Garcia-Pagan, signiﬁcant
improvement in survival was noted in high-risk cirrhosis
with variceal bleeding if TIPS was oﬀered early [61]. In this
multicentre study, patients with Child B and Child C liver
cirrhosis having acute oesophageal variceal bleeding were
randomized either to continued vasoactive drug therapy-
endoscopic band ligation or to TIPS within 72 hours of
presentation, using covered stents. A distinct improvement
in survival was noted with patients in the TIPS group than
in the pharmacotherapy-endoscopic group (97% versus 67%
at 6 weeks and 86% versus 61% at 1 year). It would be
interesting to see if the same eﬀect is noted in patients
with severe ascites and hydrothorax if TIPS is oﬀered early,
rather than wait till it gets refractory to conventional medical
therapy.
4. Conclusion
Survival of decompensated cirrhotics is largely dependent on
thecontrolofportalhypertension.TheTIPSshuntisahighly
eﬀective method in portal decompression. While the initial
use found extreme promise in controlling complications
such as variceal bleeding and ascites, the last decade has
witnessed an improved survival among decompensated
liver disease patients who have undergone TIPS, largely
due to improved devices, better patient selection, better
understanding of procedural end-points, and early use of the
procedure.
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